Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Lupuli flos*, the dried female inflorescences of *Humulus lupulus* (hops), is a botanical drug traditionally utilized for its sedative, hypnotic, and anxiolytic properties. In clinical research led by the Medical University of Graz, it has been evaluated as a phytotherapeutic intervention for the management of perioperative anxiety and pain. The pharmacological activity of *Lupuli flos* is attributed to a complex mixture of secondary metabolites, including bitter acids (humulones and lupulones) and prenylated flavonoids (such as xanthohumol). Its primary mechanism of action involves the positive allosteric modulation of GABA-A receptors, facilitating inhibitory neurotransmission. Additionally, components of the extract demonstrate agonist activity at melatonin MT1 and MT2 receptors and antagonist activity at serotonin 5-HT6 and 5-HT7 receptors, which collectively contribute to its sedative and mood-stabilizing effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lupuli flos.